Score
3
2000
pubmed
[THYMOSIN ALFA 1,A NEW BIOLOGIC RESPONSE MODIFIER FOR THE TREATMENT OF VIRAL HEPATITIS AND HEPATOCELLULAR CARCINOMA].
Martins EB. Eduardo B. MD; Tuthill C. Cynthia PHD
Key Findings
- Thymosin alpha-1 can boost the immune response against hepatitis B and C viruses.
- Clinical trials have shown modest improvements in viral load and liver function when used alongside standard antiviral therapies.
- In patients with hepatocellular carcinoma, thymosin alpha-1 has been linked to slower tumor progression and better survival when combined with other treatments.
Practical Outcomes
- For biohackers interested in liver health, thymosin alpha-1 appears promising as an adjunct to conventional antiviral or cancer therapies, but reliable dosing guidelines are lacking. Until more concrete protocols emerge, it is best used under medical supervision rather than as a DIY supplement.
Summary
Thymosin alpha-1 is a peptide that has been studied as a treatment aid for chronic hepatitis B and C infections and for liver cancer (hepatocellular carcinoma). The paper reviews how it works as a biological response modifier and summarizes clinical results showing some benefit, but it does not give detailed dosing protocols for self‑administration.
Abstract
Thymosin alpha-1 is a new biologic response modifier that has been investigated in humans for treatment of chronic hepatitis B, chronic hepatitis C, and some types of cancer, particularly hepatocellular carcinoma. All these particular aspects are here reviewed.
Study Information
Provider
pubmed
Year
2000